Philippe de Medina

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10213403/publications.pdf

Version: 2024-02-01

43 papers	2,109 citations	257450 24 h-index	265206 42 g-index
43 all docs	43 docs citations	43 times ranked	5593 citing authors

#	Article	IF	Citations
1	Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. Journal of Lipid Research, 2010, 51, 2105-2120.	4.2	528
2	Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13520-13525.	7.1	109
3	Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties. Nature Communications, 2013, 4, 1840.	12.8	101
4	Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9346-E9355.	7.1	96
5	Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy, 2009, 5, 1066-1067.	9.1	86
6	Molecular Characterization of the Microsomal Tamoxifen Binding Site. Journal of Biological Chemistry, 2004, 279, 34048-34061.	3.4	84
7	Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nature Communications, 2017, 8, 1903.	12.8	84
8	MAPK14/p38Î± confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy, 2012, 8, 1098-1112.	9.1	79
9	Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 1165-1173.	2.5	71
10	Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 491-508.	7.0	67
11	Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion. Journal of Lipid Research, 2009, 50, 2203-2211.	4.2	64
12	Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Molecular Cancer Therapeutics, 2008, 7, 3707-3718.	4.1	56
13	5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of Tamoxifen in breast cancer cells. Biochemical Pharmacology, 2013, 86, 175-189.	4.4	56
14	Synthesis and Biological Properties of New Stilbene Derivatives of Resveratrol as New Selective Aryl Hydrocarbon Modulators. Journal of Medicinal Chemistry, 2005, 48, 287-291.	6.4	55
15	Synthesis of New Alkylaminooxysterols with Potent Cell Differentiating Activities: Identification of Leads for the Treatment of Cancer and Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2009, 52, 7765-7777.	6.4	55
16	Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. Chemistry and Physics of Lipids, 2011, 164, 432-437.	3.2	51
17	Auraptene Is an Inhibitor of Cholesterol Esterification and a Modulator of Estrogen Receptors. Molecular Pharmacology, 2010, 78, 827-836.	2.3	50
18	Surprising unreactivity of cholesterol-5,6-epoxides towards nucleophiles. Journal of Lipid Research, 2012, 53, 718-725.	4.2	36

#	Article	IF	Citations
19	The NR4A nuclear receptors as potential targets for anti-aging interventions. Medical Hypotheses, 2015, 84, 135-140.	1.5	33
20	Targeting Cholesterol Homeostasis to Fight Hearing Loss: A New Perspective. Frontiers in Aging Neuroscience, 2015, 7, 3.	3.4	29
21	Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds. Frontiers in Oncology, 2015, 5, 287.	2.8	28
22	Synthesis, binding and structureâ€“affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS). Bioorganic and Medicinal Chemistry, 2000, 8, 2007-2016.	3.0	27
23	Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism. Oncotarget, 2013, 4, 911-922.	1.8	27
24	Progesterone and a phospholipase inhibitor increase the endosomal bis(monoacylglycero)phosphate content and block HIV viral particle intercellular transmission. Biochimie, 2013, 95, 1677-1688.	2.6	25
25	Natural oxyprenylated coumarins are modulators of melanogenesis. European Journal of Medicinal Chemistry, 2018, 152, 274-282.	5.5	22
26	The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2019, 192, 105390.	2.5	22
27	The novel steroidal alkaloids dendrogenin A and B promote proliferation of adult neural stem cells. Biochemical and Biophysical Research Communications, 2014, 446, 681-686.	2.1	21
28	From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metabolite. Biochimie, 2016, 130, 109-114.	2.6	21
29	The Prototypical Inhibitor of Cholesterol Esterification, Sah 58-035 [3-[Decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], Is an Agonist of Estrogen Receptors. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 139-149.	2.5	20
30	HPLC Analysis and Skin Whitening Effects of Umbelliprenin-containing Extracts of Anethum Graveolens, Pimpinella Anisum, and Ferulago Campestris. Molecules, 2019, 24, 501.	3.8	14
31	Characterization of the Degradation Profile of Umbelliprenin, a Bioactive Prenylated Coumarin of a Ferulago Species. Journal of Natural Products, 2017, 80, 2424-2431.	3.0	13
32	Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. Cancers, 2020, 12, 1725.	3.7	13
33	Dendrogenin A and B two new steroidal alkaloids increasing neural responsiveness in the deafened guinea pig. Frontiers in Aging Neuroscience, 2015, 7, 145.	3.4	11
34	Insights into the Cholecystokinin 2 Receptor Binding Site and Processes of Activation. Molecular Pharmacology, 2006, 70, 1935-1945.	2.3	8
35	Quantitative analysis of the tumor suppressor dendrogenin A using liquid chromatography tandem mass spectrometry. Chemistry and Physics of Lipids, 2017, 207, 81-86.	3.2	8
36	Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosomeâ€enriched vesicles. Journal of Extracellular Vesicles, 2022, 11, e12211.	12.2	8

#	Article	IF	Citations
37	Improvement of 5,6Î±-epoxycholesterol, 5,6Î²-epoxycholesterol, cholestane-3Î²,5Î±,6Î²-triol and 6-oxo-cholestan-3Î²,5Î±-diol recovery for quantification by GC/MS. Chemistry and Physics of Lipids, 2017, 207, 92-98.	3.2	7
38	A fast UPLCâ€“HILIC method for an accurate quantiï¬cation of dendrogenin A in human tissues. Journal of Steroid Biochemistry and Molecular Biology, 2019, 194, 105447.	2.5	7
39	Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia. Cancers, 2020, 12, 2933.	3.7	7
40	Quantitative profiling of 4'-geranyloxyferulic acid and its conjugate with l-nitroarginine methyl ester in mononuclear cells by high-performance liquid chromatography with fluorescence detection. Journal of Pharmaceutical and Biomedical Analysis, 2017, 133, 49-55.	2.8	4
41	Deciphering the metabolic secret of longevity through the analysis of metabolic response to stress on long-lived species. Medical Hypotheses, 2019, 122, 62-67.	1.5	3
42	Xenohormesis in early life: New avenues of research to explore anti-aging strategies through the maternal diet. Medical Hypotheses, 2017, 109, 126-130.	1.5	2
43	Technical note: Hapten synthesis, antibody production and development of an enzyme-linked immunosorbent assay for detection of the natural steroidal alkaloid Dendrogenin A. Biochimie, 2013, 95, 482-488.	2.6	1